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Allosteric modulation and ligand binding kinetics at the Kv11.1 channel
1. Most drugs associated with (Torsade de Pointes) TdP in humans are also as-
sociated with the Kv11.1/hERG channel block at concentrations close to the free 
plasma concentrations found in clinical use. 
Redfern, W., et al. Cardiovasc. Res. 2003, 58, 32-45.
2. Screening efforts to avoid drug blockage of the Kv11.1/hERG channel led to 
the recent discovery of novel compounds that, ironically, increase channel activity. 
Studies are needed to determine whether activators can safely counteract the conse-
quences of a reduced hERG-channel current in LQTS.
Sanguinetti, M. C.; Tristani-Firouzi, M. Nature 2006, 440, 463-469
3. In addition to classic early studies on enzymes, there are now examples of 
small molecule allosteric modulators for all superfamilies of drug targets encoded 
by the genome, including ligand- and voltage-gated ion channels, G protein-coupled 
receptors, nuclear hormone receptors, and receptor tyrosine kinases.
Christopoulos, A., et al. Pharmacol. Rev. 2014, 66, 918-947
4. Drug binding to the Kv11.1/hERG channel is likely to be a highly dynamic pro-
cess with multiple drug and channel conformations contributing to binding for any 
given drug. It is likely that the development of accurate computer models of drug 
binding kinetics combined with structural studies will be needed to fully understand 
and ultimately overcome this complex safety-pharmacology problem.
Vandenberg, J. I., et al. Physiol. Rev. 2012, 92, 1393-1478
5. An obvious strategy to reduce the proarrhythmic risk of drugs with unintended 
IKr blockade is by lowering their Kv11.1 affinity via chemical modifications. Alterna-
tively, complementary drugs that lessen the proarrhythmic risk of inadvertent Kv11.1 
blockers can be developed potentially allowing the (i) reintroduction of medicines 
previously recalled from the market because of their Kv11.1-related cardiotoxicity 
and (ii) admission of new drugs with fortuitous IKr-blocking effects.
This thesis, chapter 4
6. Negative allosteric modulators of the Kv11.1 channel could be beneficial in 
LQT syndromes induced by genetic loss-of-function or pharmacological inhibition 
of both Kv11.1 and Kv7.1 channels.
This thesis, chapter 5
7. Analyzing slow association and/or fast dissociation characteristics as a “novel 
marker” might be beneficial for profiling and reducing Kv11.1 cardiotoxicity of drug 
candidates.
This thesis, chapter 6
8. Kv11.1 blockers with similar potencies (IC50 values) but distinct binding kinet-
ics can have markedly diverse proarrhythmic properties, suggesting the necessity 
to extend Kv11.1 inhibition assays with studies on investigating the dynamics of 
drug-channel interactions.
Di Veroli, G. Y., et al. J. Cardiovasc. Electrophysiol. 2014, 25, 197-207; this 
thesis, chapter 7
9. Natural abilities are like natural plants, which need pruning by study. 
Francis Bacon
10. “Fail fast, fail cheap” is a good slogan for hERG-induced cardiotoxicity but a 
disaster for research.
11. Good scientists are always working at the edge of possibilities. The progress 
and outcome of their studies may often yield further technical and scientific prob-
lems rather than explicit and desirable answers. 
12. Thinking is a compulsory course for every Ph.D candidate to become an ex-
pert.
